Ken
Research announced its latest publication on “Global
Glaucoma Treatment Drugs Market Outlook to 2020 – New Product Launches Expected
to Boost Market” provides a comprehensive analysis of the glaucoma
treatment drugs market. The report includes the market share contributed by the
sales of generic and patented drugs globally for treatment of glaucoma.
Further, the market in the study is differentiated by various parameters such
as drug classes which include prostaglandin analogues, alpha agonist, beta
blockers, carbonic Anhydrase inhibitors, cholinergic, and combined medications.
On the basis of formulation, glaucoma treatment drugs market is categorized
into topical eye drops, semisolid dosage forms and pills. The market is also
segmented by six geographical regions across the globe – North America, Europe,
Asia Pacific, Middle East, Latin America, and Rest of the World. Detailed
snapshot on key regions of the Market which includes North America, Europe, and
Asia Pacific is included in the report to elucidate facts about the market in
detail. The study also highlights the detailed information about major drug
manufacturers in the global glaucoma treatment drugs market and their
respective shares by revenue in 2015. Analysis on pipeline products, patented
drugs available in the market, and difference between generic and patented
drugs is provided in report to assist new entrants in understanding the market
before investing in the market. Various marketing analysis factors such as
trends and developments and Porter’s five forces analysis are also added in the
study for clear understanding about the factors responsible for present
scenario of the market. The future analysis of overall global glaucoma
treatment drugs market has also been discussed along with recommendations from
analyst view, according to Research Analyst, Ken Research.
High prevalence of glaucoma in emerging economies is
demanding for awareness programs which could educate people about the disease
and treatment options. It has been estimated that more than ten million people
were suffering from glaucoma in 2015, around one-tenth among them were blind.
Similarly, it has been predicted that Glaucoma was leading cause of blindness
in Hong Kong and the diseases resulted in blindness in approximately two
million people in China in 2015. These statistics clearly advocated the need of
spreading awareness about glaucoma and available treatment options. A study
conducted in India by Department of Ophthalmology, S D M College of Medical
Sciences and Hospital, Sattur, Dharwad, Karnataka clearly defined the
unawareness about glaucoma in the market. It was concluded that minimal share
of the total subjects recruited for the study were aware about glaucoma or had
any knowledge about the disease. These statistics have attracted the attention
of various NGOs and government to spread awareness about the glaucoma and
associated treatment options. The key awareness programs included National
Program for Control of Blindness in India, Orbis Flying Eye Hospital (FEH)
Program in China, Prime Healthcare Group Glaucoma Awareness Campaign in UAE, IAPB
Vision 2020 Workshop in Indonesia, and Malaysia Glaucoma Society in Malaysia.
“In order to penetrate into the growing glaucoma
treatment drugs market, the market players could plan to invest in emerging
economies of Asia and Latin America especially India and China.
The companies should expand their marketing and sales initiatives in these
countries for providing medications in less time. Moreover, the companies could
also plan to establish their manufacturing units in Asian countries. This would
result in availability of medications in fewer prices to the patients in cost
sensitive markets” according to Research Analyst, Ken Research.
Key Topics Covered in the
Report:
• The market size of Global Glaucoma
Treatment Drugs Market
- By Revenues
• Market segmentation of Global
Glaucoma Treatment Drugs Market on the basis
- By Drug Class – Prostaglandin Analogues, Alpha Agonist,
Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, and Combined
Medications
- By Formulations – Topical Eye
Drops, Semisolid Dosage Forms, and Pills
- By Geographical Regions – North America, Europe, Asia
Pacific, Latin America, Middle East, and Rest of the World
• Snapshot on North America Glaucoma
Treatment Drugs Market
• Snapshot on Europe Glaucoma
Treatment Drugs Market
• Snapshot on Asia Pacific Glaucoma
Treatment Drugs Market
• Porter’s Five Forces Analysis for
Global Glaucoma Treatment Drugs Market
• Trends and Developments in Global
Glaucoma Treatment Drugs Market
• Snapshot on Patented Glaucoma
Treatment Drugs Market
• Generic versus Branded Glaucoma
Drugs
• Pipeline Analysis of Global
Glaucoma Treatment Drugs Market
• Competitive Landscape and Detailed
Company Profiles of the Major Market Players
• Future Outlook and Projections of
Global Glaucoma Treatment Drugs Market
• Analyst Recommendations
• Macro-economic Factors Impacting
the Global Glaucoma Treatment Drugs Market
Key Products Mentioned in the
Report
Lumigan,
Travatan Z, Combigan, Xalatan, Simbrinza Suspension, Azopt, Zioptan, Istalol,
Cosopt PF, Vasneo, Rhopressa, Roclatan, Trabodenoson, Prostaglandin Analogues,
Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Cholinergic, and
Combination Medications
Key Market Players Covered in
the Report:
Alcon,
Allergan plc, Akorn Inc., Bausch & Lomb Incorporated, Pfizer Inc, Merck
& Co. Inc, Aerie Pharmaceuticals, Inotek Pharmaceuticals, Santen
Pharmaceutical Co. Ltd
For
more coverage click on the link below:
Related Reports:
Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
